Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 59,900 shares, a growth of 215.3% from the June 30th total of 19,000 shares. Currently, 10.7% of the shares of the stock are sold short. Based on an average daily volume of 1,380,000 shares, the days-to-cover ratio is currently 0.0 days.
Salarius Pharmaceuticals Trading Down 8.9 %
NASDAQ:SLRX traded down $0.31 during trading hours on Friday, hitting $3.19. The company had a trading volume of 1,272,293 shares, compared to its average volume of 861,955. The company has a 50-day moving average of $2.92 and a 200 day moving average of $3.90. The company has a market cap of $1.91 million, a P/E ratio of -0.15 and a beta of 0.92. Salarius Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $7.92.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($3.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($53.60) by $50.32. On average, analysts forecast that Salarius Pharmaceuticals will post -214.4 earnings per share for the current year.
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
See Also
- Five stocks we like better than Salarius Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Analyst Ratings and Canadian Analyst Ratings
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 3 Fintech Stocks With Good 2021 Prospects
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.